Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Jamey Keaton

Hope for developing world as Swiss anti-malarial for newborns approved

  • Switzerland's medical products authority, Swissmedic, has granted the first approval for a malaria medicine specifically designed for infants weighing between 2 and 5kg.
  • The newly approved medication, developed by Novartis, is a lower-dose version of a tablet previously approved for older age groups.
  • Swissmedic's decision is significant as it marks only the third time the agency has used a fast-track authorisation process, in coordination with the World Health Organization, to help developing countries access needed treatment.
  • This development is crucial given that malaria remains the deadliest disease in Africa, accounting for 95 per cent of global deaths from the disease in 2023, with children account for over three-quarters of those deaths.
  • While welcomed, experts highlight the importance of transparency regarding Novartis's planned “largely not-for-profit” rollout, including pricing and distribution strategies, especially as malaria cases continue to rise and drug resistance grows.

IN FULL

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.